Community Research Advisors Group (CRAG) Statement on TBTC Study 38 (CRUSH-TB)
November 18, 2026
The Community Research Advisors Group (CRAG) welcomes the promising results from the first wave of CRUSH-TB (TBTC Study 38), presented today, Wednesday, Nov. 18, at the Union World Conference on Lung Health in Rio de Janeiro, Brazil. The findings mark an encouraging step toward developing shorter treatment options for people with drug-susceptible tuberculosis (TB). While further research is needed, the results offer renewed hope that the six-month treatment regimen used by millions of people with TB worldwide can be shortened without compromising treatment outcomes.
CRUSH-TB is a phase 2c clinical trial conducted by the U.S. Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium (TBTC). The study evaluated two four-month regimens containing bedaquiline, moxifloxacin, and pyrazinamide, combined with either delamanid or rifabutin, against the standard six-month treatment regimen. The first wave enrolled 292 participants across sites in South Africa, Uganda, Haiti, Vietnam, and the United States.
Both experimental regimens showed promising efficacy, achieving faster sputum culture conversion than the six-month standard of care. Results were particularly encouraging for the delamanid-containing regimen, which met non-inferiority criteria for the secondary efficacy measure of sustained cure at 52 weeks. These findings highlight the potential of delamanid as a component of shorter treatment regimens and support its further investigation in subsequent phases of CRUSH-TB. Importantly, the regimens use existing, marketed medicines with established safety profiles, offering a promising opportunity to build on available treatments.
CRAG congratulates the TBTC investigators, study teams, and participants who made this research possible. The results demonstrate the value of sustained investment in TB treatment research and provide an important foundation for future regimen development.
“For people affected by TB, shorter treatment means less disruption to daily life and fewer barriers to completing treatment”, explains CRAG member, Godfrey Mbulelo Tabata. “The CRUSH-TB study is an encouraging step forward, not only in exploring shorter treatment options, but also in demonstrating the value of innovative Phase 2C trial designs that assess clinical outcomes earlier in the study process.”
While shorter treatment is an important goal, duration alone does not determine whether a regimen is better for patients. People receiving TB treatment must be able to tolerate their medicines and complete treatment without unnecessary disruption to their health and daily lives.
Although a higher proportion of participants in the experimental arms experienced grade 3 or higher adverse events during 26 weeks after randomization compared with standard treatment, no unexpected safety concerns were identified. Encouragingly, the delamanid-containing regimen demonstrated favorable outcomes on other important safety measures, including fewer serious adverse events and fewer treatment discontinuations compared with standard treatment. No deaths were reported. Further analyses of treatment tolerability, including lower-grade adverse events and time to symptom resolution, are already planned and will provide valuable insights into patients’ experiences and the overall acceptability of these regimens.
CRAG also urges researchers and policymakers to carefully consider the implications of expanding the use of medicines traditionally reserved for drug-resistant TB. Growing bedaquiline resistance and limited access to drug susceptibility testing for delamanid and related medicines raise important concerns. Advances in treatment must be accompanied by investments in drug susceptibility testing, diagnostic capacity, and resistance surveillance to protect the effectiveness of these medicines.
While the use of existing medicines offers important advantages, affordability remains critical. Delamanid remains among the most expensive medicines used to treat drug-resistant TB, with a six-month treatment course costing between $800 (Viatris) and $1,190 (Otsuka) in the Global Drug Facility catalogue. If delamanid-containing regimens are eventually recommended for first-line treatment, prices must be substantially reduced to ensure equitable access, particularly in high TB-burden settings. Encouragingly, research has estimated that generic delamanid 50 mg could be produced at a target price of just US$30–96 for a six-month course, demonstrating the potential for significant price reductions. Ensuring affordable access to delamanid will be essential to realizing the promise of these new treatment regimens.
“While the prospect of shorter TB treatment is exciting, patient safety must remain at the forefront,” stated Dr.Barbara Seaworth, CRAG co-chair. “We need to better understand the tolerability, drug interactions, and long-term effectiveness of these regimens, including among populations often underrepresented in clinical trials. Equally important is ensuring that promising new treatments are affordable and accessible to everyone who needs them.”
CRAG welcomes the continuation of the CRUSH-TB trial, including plans to expand enrollment among populations often underrepresented in TB treatment trials, such as people living with HIV, people with diabetes, older adults, and adolescents. Further research must establish whether promising efficacy and safety findings extend to these populations. CRAG also encourages the inclusion of children in future research, particularly as all medicines included in the CRUSH-TB regimens already have pediatric safety and pharmacokinetic data available, providing a strong foundation for evaluating these regimens in children.
The CRUSH-TB findings are an encouraging reminder that progress toward shorter TB treatment is possible. As research continues, CRAG calls on investigators, funders, pharmaceutical companies, and policymakers to ensure that future treatment advances are not only shorter and effective, but also safe, tolerable, affordable, and accessible to all people affected by TB.
About CRAG
The Community Research Advisors Group (CRAG) is an international, community-driven advisory body that works to ensure the meaningful representation and engagement of affected communities in research conducted by the U.S. Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium (TBTC). This group of research-literate activists and advocates supports a robust, comprehensive, and innovative TBTC research agenda that is responsive to community needs as well as scientific priorities. The CRAG is coordinated and hosted by the Treatment Action Group.

